M Tajes1,2, C Díez-López1,2,3,4, C Enjuanes1,2,5, P Moliner1,2,5, J L Ferreiro1,2, A Garay1,2,5, S Jiménez-Marrero1,2,5, S Yun1,5,6, S G Sosa1,2, L Alcoberro1,2,5, J González-Costello1,2,3,4, E García-Romero1,2,3, L Yañez-Bisbe7, B Benito7,8,9, J Comín-Colet10,11,12,13. 1. Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. 2. Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain. 3. Advanced Heart Failure and Heart Transplant Unit, Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain. 4. Department of Clinical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain. 5. Community Heart Failure Program, Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain. 6. Department of Internal Medicine, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain. 7. Vascular Biology and Metabolism Program, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain. 8. Cardiology Department, Hospital Vall d'Hebron Hospital, Barcelona, Spain. 9. Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. 10. Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. josepcomin@gmail.com. 11. Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain. josepcomin@gmail.com. 12. Community Heart Failure Program, Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain. josepcomin@gmail.com. 13. Department of Clinical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain. josepcomin@gmail.com.
Abstract
BACKGROUND: Iron deficiency (ID) is common in patients with heart failure (HF) and is associated with poor outcomes, yet its role in the pathophysiology of HF is not well-defined. We sought to determine the consequences of HF neurohormonal activation in iron homeostasis and mitochondrial function in cardiac cells. METHODS: HF was induced in C57BL/6 mice by using isoproterenol osmotic pumps and embryonic rat heart-derived H9c2 cells were subsequently challenged with Angiotensin II and/or Norepinephrine. The expression of several genes and proteins related to intracellular iron metabolism were assessed by Real time-PCR and immunoblotting, respectively. The intracellular iron levels were also determined. Mitochondrial function was analyzed by studying the mitochondrial membrane potential, the accumulation of radical oxygen species (ROS) and the adenosine triphosphate (ATP) production. RESULTS: Hearts from isoproterenol-stimulated mice showed a decreased in both mRNA and protein levels of iron regulatory proteins, transferrin receptor 1, ferroportin 1 and hepcidin compared to control mice. Furthermore, mitoferrin 2 and mitochondrial ferritin were also downregulated in the hearts from HF mice. Similar data regarding these key iron regulatory molecules were found in the H9c2 cells challenged with neurohormonal stimuli. Accordingly, a depletion of intracellular iron levels was found in the stimulated cells compared to non-stimulated cells, as well as in the hearts from the isoproterenol-induced HF mice. Finally, neurohormonal activation impaired mitochondrial function as indicated by the accumulation of ROS, the impaired mitochondrial membrane potential and the decrease in the ATP levels in the cardiac cells. CONCLUSIONS: HF characteristic neurohormonal activation induced changes in the regulation of key molecules involved in iron homeostasis, reduced intracellular iron levels and impaired mitochondrial function. The current results suggest that iron could be involved in the pathophysiology of HF.
BACKGROUND:Iron deficiency (ID) is common in patients with heart failure (HF) and is associated with poor outcomes, yet its role in the pathophysiology of HF is not well-defined. We sought to determine the consequences of HF neurohormonal activation in iron homeostasis and mitochondrial function in cardiac cells. METHODS: HF was induced in C57BL/6 mice by using isoproterenol osmotic pumps and embryonic rat heart-derived H9c2 cells were subsequently challenged with Angiotensin II and/or Norepinephrine. The expression of several genes and proteins related to intracellular iron metabolism were assessed by Real time-PCR and immunoblotting, respectively. The intracellular iron levels were also determined. Mitochondrial function was analyzed by studying the mitochondrial membrane potential, the accumulation of radical oxygen species (ROS) and the adenosine triphosphate (ATP) production. RESULTS: Hearts from isoproterenol-stimulated mice showed a decreased in both mRNA and protein levels of iron regulatory proteins, transferrin receptor 1, ferroportin 1 and hepcidin compared to control mice. Furthermore, mitoferrin 2 and mitochondrial ferritin were also downregulated in the hearts from HF mice. Similar data regarding these key iron regulatory molecules were found in the H9c2 cells challenged with neurohormonal stimuli. Accordingly, a depletion of intracellular iron levels was found in the stimulated cells compared to non-stimulated cells, as well as in the hearts from the isoproterenol-induced HF mice. Finally, neurohormonal activation impaired mitochondrial function as indicated by the accumulation of ROS, the impaired mitochondrial membrane potential and the decrease in the ATP levels in the cardiac cells. CONCLUSIONS: HF characteristic neurohormonal activation induced changes in the regulation of key molecules involved in iron homeostasis, reduced intracellular iron levels and impaired mitochondrial function. The current results suggest that iron could be involved in the pathophysiology of HF.
Authors: Cristina Enjuanes; Ijsbrand T Klip; Jordi Bruguera; Merce Cladellas; Piotr Ponikowski; Waldemar Banasiak; Dirk J van Veldhuisen; Peter van der Meer; Ewa A Jankowska; Josep Comín-Colet Journal: Int J Cardiol Date: 2014-04-03 Impact factor: 4.164
Authors: Daniel G Kramer; Thomas A Trikalinos; David M Kent; George V Antonopoulos; Marvin A Konstam; James E Udelson Journal: J Am Coll Cardiol Date: 2010-07-27 Impact factor: 24.094
Authors: Ijsbrand T Klip; Josep Comin-Colet; Adriaan A Voors; Piotr Ponikowski; Cristina Enjuanes; Waldemar Banasiak; Dirk J Lok; Piotr Rosentryt; Ainhoa Torrens; Lech Polonski; Dirk J van Veldhuisen; Peter van der Meer; Ewa A Jankowska Journal: Am Heart J Date: 2013-02-22 Impact factor: 4.749
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur Heart J Date: 2016-05-20 Impact factor: 29.983
Authors: Ridha I S Alnuwaysir; Martijn F Hoes; Dirk J van Veldhuisen; Peter van der Meer; Niels Grote Beverborg Journal: J Clin Med Date: 2021-12-27 Impact factor: 4.964
Authors: Monika Kasztura; Liliana Kiczak; Urszula Pasławska; Jacek Bania; Adrian Janiszewski; Alicja Tomaszek; Maciej Zacharski; Agnieszka Noszczyk-Nowak; Robert Pasławski; Aleksandra Tabiś; Piotr Kuropka; Piotr Dzięgiel; Piotr Ponikowski Journal: Int J Mol Sci Date: 2022-01-18 Impact factor: 5.923